A notable milestone in this field was the development of imatinib, a tyrosine kinase inhibitor that revolutionized the management of chronic myeloid leukemia (CML) by specifically targeting the BCR-ABL protein responsible for the pathology [47]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.